Showing results (481-490 of 525) with videos related to

Sort By:
Pageof 53
Proceedings of the National Academy of Sciences of the United States of America|June 2, 2016
Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaquesHui Li, Shuyi Wang, Rui Kong, et al.
The Lancet. HIV|May 29, 2025
Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, a V2 specific HIV-1 broadly neutralising antibody, infused intravenously or subcutaneously in people without HIV-1 in the USA (HVTN 140/HPTN 101 part A): a first-in-human, phase 1 randomised trialKelly E Seaton, Carmen A Paez, Chenchen Yu, et al.
Nature Medicine|May 23, 2018
HIV vaccine candidate activation of hypoxia and the inflammasome in CD14<sup>+</sup> monocytes is associated with a decreased risk of SIV<sub>mac251</sub> acquisitionMonica Vaccari, Slim Fourati, Shari N Gordon, et al.
Plos One|November 1, 2011
H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccinationM Anthony Moody, Ruijun Zhang, Emmanuel B Walter, et al.
Nature Medicine|May 13, 2022
Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trialBoris Julg, Kathryn E Stephenson, Kshitij Wagh, et al.
Nature|September 28, 2018
Combination therapy with anti-HIV-1 antibodies maintains viral suppressionPilar Mendoza, Henning Gruell, Lilian Nogueira, et al.
The Journal of Experimental Medicine|September 5, 2024
Use of 3M-052-AF with Alum adjuvant in HIV trimer vaccine induces human autologous neutralizing antibodiesWilliam O Hahn, K Rachael Parks, Mingchao Shen, et al.
Medrxiv : the Preprint Server for Health Sciences|May 20, 2024
HIV BG505 SOSIP.664 trimer with 3M-052-AF/alum induces human autologous tier-2 neutralizing antibodiesWilliam O Hahn, K Rachael Parks, Mingchao Shen, et al.
Emerging Microbes & Infections|April 7, 2025
A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell responses among 13 HIV vaccine trialsZoe Moodie, Shuying Sue Li, Elena E Giorgi, et al.
Nature Medicine|October 8, 2021
Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trialKathryn E Stephenson, Boris Julg, C Sabrina Tan, et al.
Pageof 53